OCCUPATIONAL THERAPY CREATES PROFOUND IMPACTS ON CLIENT AND PATIENT LIVES
Margeaux Bartholomew-Carle
Occupational Therapist &
Chief Executive Officer, Ardant
PEOPLE IN HEALTH CARE
Filmed in Adelaide, South Australia | December 2024
In Australia, access to allied health services such as occupational therapy is increasingly challenging. Barriers like long wait times affect over 600,000 National Disability Insurance Scheme (NDIS) and 1.5 million aged care participants. With both cohorts expected to grow exponentially in coming years, the pressure on an already stretched system is set to increase.
Australian Health Journal met with one Occupational Therapist who encourages those entering the profession to embrace continuous learning and seek mentorship to maximise their impact on clients’ lives. Through her company she has a nation-wide mission to transform client access to allied health services like occupational therapy using artificial intelligence (AI).
Margeaux Bartholomew-Carle is an Adelaide based registered Occupational Therapist and the Founder and CEO of Ardant.
Throughout her career, Margeaux has worked in various settings, including aged care, disability, assistive technology, prescription, and mental health. This diverse experience has deepened her understanding of the different needs among client groups.
A significant turning point came when she worked as a solo practitioner and realised that the heavy administrative burden often kept her from important family moments, especially while her father was in the hospital with advanced prostate cancer. This experience motivated her to establish Ardant, focused on enabling OTs to prioritise client care over administrative tasks.
Under her leadership, Ardant has created an all-in-one online practice management platform designed to reduce administrative burdens for independent occupational therapists across Australia, ultimately enhancing access to OT services and improving client outcomes.
Margeaux believes that the role of occupational therapists is gaining recognition, particularly with the introduction of the NDIS, but acknowledges there are persistent misconceptions about the profession. To raise awareness, she advocates for targeted campaigns to educate GPs, health professionals, and the public about the value of OT in primary healthcare.
-
Shaping Health, Advancing Nursing through training, upskilling & scholarships
The Chief Executive Officer of Australian College of Nursing, Adjunct Professor Kylie Ward FACN spoke in depth with Australian Health Journal about:
The key recommendations in ACN’s pre-budget submission to Federal Government
The impact of legislation requiring a Registered Nurse (RN) at every residential aged care facility from 1st July 2023
Why scholarships in nursing leadership are important
Why ACN has recommended the Government fund 200 Pacific nurses in 15 nations for the online ACN postgraduate certification
The need for a multi-pronged approach that includes skilled migration in rebuilding the nursing workforceIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
Journey of an ICU Nurse on International Nurses Day 2025
Kate Leigh is a clinical nurse at the Sir Charles Gairdner Hospital Intensive Care Unit in Perth, Western Australia, with seven and a half years of experience in intensive care, having started her career in London as a new graduate nurse. Initially focused on haematology, she found herself drawn to ICU after meeting a confident and knowledgeable nurse during a discharge. Inspired by his expertise and assuredness, Kate decided to pursue a transfer to Critical Care after seeing an internal advertisement that highlighted educational opportunities and professional development programs.
-
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
